TW202220650A - 5-甲基-1,2,4-噁二唑-3-基化合物之低劑量療法及調配物 - Google Patents

5-甲基-1,2,4-噁二唑-3-基化合物之低劑量療法及調配物 Download PDF

Info

Publication number
TW202220650A
TW202220650A TW110126729A TW110126729A TW202220650A TW 202220650 A TW202220650 A TW 202220650A TW 110126729 A TW110126729 A TW 110126729A TW 110126729 A TW110126729 A TW 110126729A TW 202220650 A TW202220650 A TW 202220650A
Authority
TW
Taiwan
Prior art keywords
compound
day
total dose
dose
pharmaceutically acceptable
Prior art date
Application number
TW110126729A
Other languages
English (en)
Chinese (zh)
Inventor
威廉 布萊恩 奇爾巴薩
達斯汀 詹姆斯 莫高
Original Assignee
美商美國禮來大藥廠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商美國禮來大藥廠 filed Critical 美商美國禮來大藥廠
Publication of TW202220650A publication Critical patent/TW202220650A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
TW110126729A 2020-07-23 2021-07-21 5-甲基-1,2,4-噁二唑-3-基化合物之低劑量療法及調配物 TW202220650A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063055362P 2020-07-23 2020-07-23
US63/055,362 2020-07-23

Publications (1)

Publication Number Publication Date
TW202220650A true TW202220650A (zh) 2022-06-01

Family

ID=77338898

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110126729A TW202220650A (zh) 2020-07-23 2021-07-21 5-甲基-1,2,4-噁二唑-3-基化合物之低劑量療法及調配物

Country Status (21)

Country Link
US (1) US20230338349A1 (cg-RX-API-DMAC7.html)
EP (1) EP4185291B1 (cg-RX-API-DMAC7.html)
JP (1) JP2023535034A (cg-RX-API-DMAC7.html)
KR (1) KR20230043905A (cg-RX-API-DMAC7.html)
CN (1) CN116323604A (cg-RX-API-DMAC7.html)
AR (1) AR123031A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021312894B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023000975A2 (cg-RX-API-DMAC7.html)
CA (1) CA3186808A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023000194A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023000594A2 (cg-RX-API-DMAC7.html)
DO (1) DOP2023000009A (cg-RX-API-DMAC7.html)
EC (1) ECSP23005057A (cg-RX-API-DMAC7.html)
ES (1) ES3039536T3 (cg-RX-API-DMAC7.html)
IL (1) IL300023A (cg-RX-API-DMAC7.html)
JO (1) JOP20230018A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023000993A (cg-RX-API-DMAC7.html)
PE (1) PE20231031A1 (cg-RX-API-DMAC7.html)
PH (1) PH12023550177A1 (cg-RX-API-DMAC7.html)
TW (1) TW202220650A (cg-RX-API-DMAC7.html)
WO (1) WO2022020663A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3243602A1 (en) 2022-02-03 2023-08-10 Eli Lilly And Company Regional Tau Imaging for the Diagnosis and Treatment of Alzheimer's Disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107735190B (zh) * 2016-07-22 2019-11-26 深圳市大富科技股份有限公司 Usb金属管件加工设备及其上模板
TWI654978B (zh) * 2017-01-27 2019-04-01 美商美國禮來大藥廠 5-甲基-1,2,4-二唑-3-基化合物
EP3829634A1 (en) * 2018-07-31 2021-06-09 Eli Lilly and Company Combination therapy

Also Published As

Publication number Publication date
CL2023000194A1 (es) 2023-07-21
EP4185291C0 (en) 2025-07-09
CA3186808A1 (en) 2022-01-27
AU2021312894B2 (en) 2025-09-11
PE20231031A1 (es) 2023-07-10
IL300023A (en) 2023-03-01
BR112023000975A2 (pt) 2023-02-07
KR20230043905A (ko) 2023-03-31
CN116323604A (zh) 2023-06-23
ES3039536T3 (en) 2025-10-22
ECSP23005057A (es) 2023-02-28
AR123031A1 (es) 2022-10-26
MX2023000993A (es) 2023-03-01
PH12023550177A1 (en) 2024-03-18
AU2021312894A1 (en) 2023-02-23
EP4185291A1 (en) 2023-05-31
US20230338349A1 (en) 2023-10-26
JOP20230018A1 (ar) 2023-01-23
DOP2023000009A (es) 2023-02-15
CO2023000594A2 (es) 2023-01-26
WO2022020663A1 (en) 2022-01-27
EP4185291B1 (en) 2025-07-09
JP2023535034A (ja) 2023-08-15

Similar Documents

Publication Publication Date Title
JP4938905B2 (ja) 選択的s1p1レセプターアゴニストの投与法
JP2024081667A (ja) ポンペ病の処置のための投与計画
EP4110326B1 (en) Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
TW202304424A (zh) 包含依維莫司和安森司群的組合
JP2018538273A (ja) 虚血性脳卒中を処置するための組成物および方法
TWI922768B (zh) 包含cdk4抑制劑之用於治療癌症之方法及給藥方案
JP2017510607A (ja) S1p調節剤即時放出投与レジメン
WO2004054574A1 (ja) 経口固形医薬
JP7818412B2 (ja) デュラグルチドを使用する方法およびデュラグルチドを含有する組成物
EP3793543A1 (en) Methods and compositions for treatment of alzheimer's disease
JP2024539476A5 (cg-RX-API-DMAC7.html)
JP2005528414A (ja) 肝臓癌および他の癌疾患の処置用エポチロン誘導体
EP4185291B1 (en) Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound
JP6454436B1 (ja) ペマフィブラートを含有する医薬
JP2005526022A5 (ja) 関節リウマチの処置
JP6692755B2 (ja) アルツハイマー病(ad)の処置および予防
WO2022238884A1 (en) Dosing regimens
HK40084518B (en) Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound
HK40084518A (en) Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound
JP6420923B1 (ja) 医薬
EP4734986A1 (en) Therapeutic uses and doses of lp(a) disrupter compounds
JP2025517624A (ja) パーキンソン病の進行を低減するためのボドバチニブ
TW202510848A (zh) 用於治療癌症之psma靶向放射性藥物
EA052714B1 (ru) Фармацевтическая композиция, содержащая производные дифенилдиазола, и способ применения